search icon
plrx-img

Pliant Therapeutics Inc, Common Stock

PLRX

NSQ

$1.34

+$0.01

(0.75%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$84.10M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
712.31K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.44
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.1 L
$16.1 H
$1.34

About Pliant Therapeutics Inc, Common Stock

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePLRXSectorS&P500
1-Week Return-2.19%0.86%-1.29%
1-Month Return-10.67%-2.58%10.63%
3-Month Return-55.78%-10.87%-2.43%
6-Month Return-89.68%-8.73%-2.14%
1-Year Return-90.55%-10.19%10%
3-Year Return-72.82%0.5%46.86%
5-Year Return-93.71%32.08%97.3%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue41.82M7.57M9.69M1.58M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":18.11,"profit":true},{"date":"2022-12-31","value":23.16,"profit":true},{"date":"2023-12-31","value":3.78,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-3.20M3.68M1.84M2.13M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":87.04,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.01,"profit":true},{"date":"2024-12-31","value":57.73,"profit":true}]
Gross Profit41.82M7.57M6.00M1.58M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":18.11,"profit":true},{"date":"2022-12-31","value":14.36,"profit":true},{"date":"2023-12-31","value":3.78,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%100.00%61.99%100.00%-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses83.46M27.56M136.88M185.72M228.37M[{"date":"2020-12-31","value":36.55,"profit":true},{"date":"2021-12-31","value":12.07,"profit":true},{"date":"2022-12-31","value":59.94,"profit":true},{"date":"2023-12-31","value":81.33,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(41.65M)(19.99M)(127.20M)(184.15M)(228.37M)[{"date":"2020-12-31","value":-4164500000,"profit":false},{"date":"2021-12-31","value":-1998600000,"profit":false},{"date":"2022-12-31","value":-12720000000,"profit":false},{"date":"2023-12-31","value":-18414500000,"profit":false},{"date":"2024-12-31","value":-22836500000,"profit":false}]
Total Non-Operating Income/Expense590.00K544.00K7.76M42.03M36.12M[{"date":"2020-12-31","value":1.4,"profit":true},{"date":"2021-12-31","value":1.29,"profit":true},{"date":"2022-12-31","value":18.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.94,"profit":true}]
Pre-Tax Income(41.53M)(19.71M)(123.32M)(161.34M)(210.30M)[{"date":"2020-12-31","value":-4153300000,"profit":false},{"date":"2021-12-31","value":-1971400000,"profit":false},{"date":"2022-12-31","value":-12332100000,"profit":false},{"date":"2023-12-31","value":-16133600000,"profit":false},{"date":"2024-12-31","value":-21030400000,"profit":false}]
Income Taxes(1.79M)(1.81M)(1.82M)1.67M-[{"date":"2020-12-31","value":-106.87,"profit":false},{"date":"2021-12-31","value":-108,"profit":false},{"date":"2022-12-31","value":-108.96,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(39.74M)(17.91M)(121.50M)(163.01M)-[{"date":"2020-12-31","value":-3974500000,"profit":false},{"date":"2021-12-31","value":-1790700000,"profit":false},{"date":"2022-12-31","value":-12149800000,"profit":false},{"date":"2023-12-31","value":-16300910500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(41.53M)(97.26M)(123.32M)(155.29M)(210.30M)[{"date":"2020-12-31","value":-4153300000,"profit":false},{"date":"2021-12-31","value":-9726300000,"profit":false},{"date":"2022-12-31","value":-12332100000,"profit":false},{"date":"2023-12-31","value":-15528700000,"profit":false},{"date":"2024-12-31","value":-21030400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(39.74M)(17.91M)(121.50M)(161.34M)(210.30M)[{"date":"2020-12-31","value":-3974500000,"profit":false},{"date":"2021-12-31","value":-1790700000,"profit":false},{"date":"2022-12-31","value":-12149800000,"profit":false},{"date":"2023-12-31","value":-16133600000,"profit":false},{"date":"2024-12-31","value":-21030400000,"profit":false}]
EPS (Diluted)(2.81)(2.71)(2.97)(2.76)(3.47)[{"date":"2020-12-31","value":-281,"profit":false},{"date":"2021-12-31","value":-271,"profit":false},{"date":"2022-12-31","value":-297,"profit":false},{"date":"2023-12-31","value":-276,"profit":false},{"date":"2024-12-31","value":-347,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PLRX
Cash Ratio 10.84
Current Ratio 11.03

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PLRX
ROA (LTM) -33.89%
ROE (LTM) -63.22%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PLRX
Debt Ratio Lower is generally better. Negative is bad. 0.25
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.75

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PLRX
Trailing PE NM
Forward PE NM
P/S (TTM) 3071.82
P/B 0.32
Price/FCF NM
EV/R 1376.69
EV/Ebitda NM

FAQs

What is Pliant Therapeutics Inc share price today?

Pliant Therapeutics Inc (PLRX) share price today is $1.34

Can Indians buy Pliant Therapeutics Inc shares?

Yes, Indians can buy shares of Pliant Therapeutics Inc (PLRX) on Vested. To buy Pliant Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PLRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pliant Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Pliant Therapeutics Inc (PLRX) via the Vested app. You can start investing in Pliant Therapeutics Inc (PLRX) with a minimum investment of $1.

How to invest in Pliant Therapeutics Inc shares from India?

You can invest in shares of Pliant Therapeutics Inc (PLRX) via Vested in three simple steps:

  • Click on Sign Up or Invest in PLRX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pliant Therapeutics Inc shares
What is Pliant Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Pliant Therapeutics Inc (PLRX) is $16.1. The 52-week low price of Pliant Therapeutics Inc (PLRX) is $1.1.

What is Pliant Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pliant Therapeutics Inc (PLRX) is 0.32

What is the Market Cap of Pliant Therapeutics Inc?

The market capitalization of Pliant Therapeutics Inc (PLRX) is $84.10M

What is Pliant Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Pliant Therapeutics Inc is PLRX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top